EMA Authorised: Bimervax (SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion dimer produced by recombinant DNA technology) — Hipra Human Health S.L.

View source ↗

Summary

EMA authorised Bimervax, a SARS-CoV-2 RBD-fusion dimer vaccine, for COVID-19 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Virus Infection

Drugs mentioned

• BIMERVAX

Snippet

Status: Authorised. Therapeutic area: COVID-19 virus infection. MAH: Hipra Human Health S.L.. Decision date: 21/05/2026